We therefore tested multiple cytostatic drugs for their impact on tumor cell killing as well as in in vivo immunization model in which T cell priming requires antigen cross-presentation by activated DCs, using agonist anti-CD40 Abs as the dendritic cell (DC)-activating signal. This evidence concerns the gene CD40 and neoplasm.